1. Home
  2. TLRY vs CADL Comparison

TLRY vs CADL Comparison

Compare TLRY & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tilray Brands Inc.

TLRY

Tilray Brands Inc.

HOLD

Current Price

$5.31

Market Cap

688.9M

Sector

Health Care

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$8.84

Market Cap

551.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLRY
CADL
Founded
N/A
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.9M
551.7M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
TLRY
CADL
Price
$5.31
$8.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$72.33
$19.00
AVG Volume (30 Days)
7.0M
2.3M
Earning Date
04-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
$8.79
N/A
Revenue Next Year
$19.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$4.35
52 Week High
$15.70
$9.27

Technical Indicators

Market Signals
Indicator
TLRY
CADL
Relative Strength Index (RSI) 32.23 74.10
Support Level $1.12 $4.80
Resistance Level $7.01 N/A
Average True Range (ATR) 0.25 0.61
MACD -0.07 0.14
Stochastic Oscillator 4.99 84.97

Price Performance

Historical Comparison
TLRY
CADL

About TLRY Tilray Brands Inc.

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: